Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes (NCT05687110)

🧪 Interventions in This Study

• Novobiocin Sodium (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• City of Hope Comprehensive Cancer Center — Duarte, California
• UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Los Angeles General Medical Center — Los Angeles, California
• USC / Norris Comprehensive Cancer Center — Los Angeles, California
• UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
• University of California Davis Comprehensive Cancer Center — Sacramento, California
• UC San Diego Medical Center - Hillcrest — San Diego, California
• University of Chicago Comprehensive Cancer Center — Chicago, Illinois
• National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
• National Institutes of Health Clinical Center — Bethesda, Maryland
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• NYU Langone Hospital - Long Island — Mineola, New York
• Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
• Ohio State University Comprehensive Cancer Center — Columbus, Ohio
• University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
• Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
• Fred Hutchinson Cancer Center — Seattle, Washington
• University of Washington Medical Center - Montlake — Seattle, Washington
• University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
• University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
• University Health Network-Princess Margaret Hospital — Toronto, Ontario

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Email: becomingapatient@coh.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Malignant Solid Neoplasm

• Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial — Birmingham, Alabama
• Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors — Houston, Texas
• Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors — Boston, Massachusetts
• Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression — Houston, Texas
• Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer — Phoenix, Arizona
• Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors — Sacramento, California

Explore by condition: All Metastatic Malignant Solid Neoplasm clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.